Postoperative Weight Loss After Antiobesity Medications and Revision Risk After Joint Replacement
Authors' conclusion
In this cohort study using a target trial emulation, a higher proportion of weight loss after initiating antiobesity medications within 1 year was associated with a lower risk of 5-year and 10-year revision among patients with obesity undergoing joint replacement. These results suggest that antiobesity medication use, with relatively safe and sustainable weight loss, may be an effective strategy for improving implant survivorship of hip and knee replacements in the obese population.
Study context
- Population
- Patients with obesity who underwent hip or knee replacement and initiated antiobesity medications (orlistat, sibutramine, GLP-1 RA, rimonabant); IQVIA Medical Research Database (2000–2023); mean age 64.7 years, 62.9% women
- Participants
- 3,691 patients
- Exposure
- Small-to-moderate (2%-10%) or large (≥10%) weight loss within 1 year after initiating antiobesity medications vs weight gain or stable
- Outcome
- Revision after initiation of antiobesity medications
- Follow-up
- 5 and 10 years
Methodological detailstarget trial emulation
- Target trial emulation
Main finding
As reported in the abstract
Revision · 5 years
Each group vs weight gain or stableHazard ratio (95% CI)
Small-to-moderate weight loss
0.75(0.55–1.04)
Large weight loss
0.57(0.36–0.91)
Observational data: associations, not effects.
Further findings
| Outcome | HR (95% CI) | |
|---|---|---|
| Revision, knee replacement subgroupSmall-to-moderate weight lossvs Weight gain or stable | 0.55 (0.32–0.93) | |
| Revision, knee replacement subgroupLarge weight lossvs Weight gain or stable | 0.49 (0.25–0.97) | |
| Revision, hip replacement subgroupSmall-to-moderate weight lossvs Weight gain or stable | 0.82 (0.54–1.25) | |
| Revision, hip replacement subgroupLarge weight lossvs Weight gain or stable | 0.53 (0.30–0.93) | |
| 0.20.5125Hazard ratio (log scale) |
Revision · 10 years
- Consistent findings for association of weight loss with 10-year revision risk
Original publication
Postoperative Weight Loss After Antiobesity Medications and Revision Risk After Joint Replacement. JAMA Netw Open. Published 3 February 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →